Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications
Emotional distress: the hidden barrier to immunotherapy success in advanced non-small cell lung cancer.
Journal: Translational lung cancer research
Published: January 09, 2025
Comprehensive Review of ROS1 Tyrosine Kinase Inhibitors-Classified by Structural Designs and Mutation Spectrum (Solvent Front Mutation [G2032R] and Central β-Sheet 6 [Cβ6] Mutation [L2086F]).
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: October 24, 2023
Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced ALK- or ROS1-Rearranged NSCLC: A Brief Report.
Journal: JTO clinical and research reports
Published: April 20, 2023
In Response to Dr. Steven Sorscher.
Journal: JTO clinical and research reports
Published: January 19, 2023
CodeBreak 200: Sotorasib Has Not Broken the KRASG12C Enigma Code.
Journal: Lung Cancer (Auckland, N.Z.)
Published: January 03, 2023
Low-Dose Computed Tomography (LDCT) Lung Cancer Screening in Asian Female Never-Smokers Is as Efficacious in Detecting Lung Cancer as in Asian Male Ever-Smokers: A Systematic Review and Meta-Analysis.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: December 11, 2022
Spotlight on Furmonertinib (Alflutinib, AST2818). The Swiss Army Knife (del19, L858R, T790M, Exon 20 Insertions, "uncommon-G719X, S768I, L861Q") Among the Third-Generation EGFR TKIs?
Journal: Lung Cancer (Auckland, N.Z.)
Published: August 16, 2022
Moving the Needle Cautiously in Targeting One of the Most Often Acquired Receptor Tyrosine Fusion (RET Fusion) Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors.
Journal: JTO clinical and research reports
Published: June 04, 2022
A High Percentage of NSCLC With Germline CHEK2 Mutation Harbors Actionable Driver Alterations: Survey of a Cancer Genomic Database and Review of Literature.
Journal: JTO clinical and research reports
Published: May 27, 2022
Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation.
Journal: Lung Cancer (Auckland, N.Z.)
Published: January 30, 2022
Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib.
Journal: Lung Cancer (Auckland, N.Z.)
Published: January 22, 2022
Last Updated: 09/26/2026